Drug details
Elfabrio (pegunigalsidase alfa-iwxj injection)
type of Enzymes, Metabolic
Elfabrio (pegunigalsidase alfa-iwxj) is a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme indicated for the treatment of adults with confirmed Fabry disease.
This drug may have the following side effects:
- nausea,
- diarrhea,
- back pain,
- headache,
- fatigue,
- runny or stuffy nose,
- pain in extremities, and
- sinus infection (sinusitis).
The following drugs are related to Elfabrio, either as a replacement or used together:
- Fabrazyme (agalsidase beta)
- Galafold (migalastat capsules)